The dermatological drugs market is experiencing unprecedented momentum following the World Health Assembly's historic resolution and a wave of FDA and EMA approvals in 2025.
Lifescience & Healthcare
The dermatological drugs market is experiencing unprecedented momentum following the World Health Assembly's historic resolution and a wave of FDA and EMA approvals in 2025.
The Seventy-ninth World Health Assembly, convening in May 2025, adopted a landmark resolution formally recognizing skin diseases as a global health priority. This historic declaration comes as the Global Burden of Disease Study 2021 revealed that approximately 4.69 billion new cases of skin and subcutaneous diseases are responsible for 41.9 million Disability Adjusted Life Years Lost globally, ranking skin conditions among the top 10 causes of disability worldwide. The WHO estimates that skin conditions affect approximately 1.8 billion people at any point in time. Psoriasis affects approximately 2% to 3% of the global population, while atopic dermatitis affects up to 20% of children and 1% to 3% of adults worldwide. The WHA resolution mandates country-level coordinated action across all skin diseases through strengthening primary care systems, expanding access to affordable diagnostics and treatments, integrating skin health into disability and mental health policies, and supporting expanded research and surveillance. This policy shift is expected to catalyze unprecedented investment in dermatological research and development, driving innovation across biologic therapies, JAK inhibitors, and novel topical formulations worldwide.The European Medicines Agency's Committee for Medicinal Products for Human Use recommended several key dermatological therapies for EU-wide marketing authorization. In January 2025, the EMA recommended Nemluvio (nemolizumab) for the treatment of atopic dermatitis and prurigo nodularis. The CHMP also recommended Yesintek (ustekinumab) biosimilar for plaque psoriasis, psoriatic arthritis, and Crohn's disease. In August 2025, the CHMP issued a positive opinion for Winlevi (clascoterone 10 mg/g cream) for the treatment of acne vulgaris. The European Commission subsequently granted marketing authorization across 17 European countries.
According to the research report "Global Dermatological Drugs Market Outlook, 2031," published by Bonafide Research, the Global Dermatological Drugs market was valued at more than USD 32.76Billion in 2025, and expected to reach a market size of more than USD 50.98 Billion by 2031 with the CAGR of 7.84% from 2026-2031. The year 2025 marked a remarkable period of innovation in dermatology, with regulatory authorities worldwide granting approvals for a wide range of therapies spanning chronic inflammatory skin diseases, rare genetic disorders, and oncology. These approvals reflect significant advancements in targeted treatments, biologics, gene therapy, and device-based interventions. The U.S. Food and Drug Administration approved several groundbreaking dermatological therapies in 2025. In April, the FDA approved prademagene zamikeracel (Zevaskyn; Abeona Therapeutics) as the first autologous, cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), marking a monumental advance in regenerative dermatology. The phase 3 VIITAL study demonstrated that 81% of wounds treated with Zevaskyn showed 50% or more healing at six months compared with 16% of matched control wounds treated with standard of care. In July, LEO Pharma secured FDA approval for Anzupgo (delgocitinib) cream as the first and only treatment for chronic hand eczema in adults. This topical pan-JAK inhibitor offers a steroid-free option for patients who have not responded adequately to traditional topical treatments. Additional notable approvals included dupilumab (Dupixent; Regeneron and Sanofi) for chronic spontaneous urticaria in patients 12 years and older—the first new targeted therapy for CSU in more than a decade and roflumilast 0.3% foam (Zoryve; Arcutis Biotherapeutics) for plaque psoriasis of the scalp and body in patients 12 years and older, marking the first branded topical foam for psoriasis. AbbVie continues to demonstrate exceptional performance in the immunology space, with its sixth-place revenue ranking largely credited to the success of Skyrizi and Rinvoq. The psoriasis treatment market exceeded $29 billion in 2025, with biologics accounting for approximately 44% of the total and the IL-23 inhibitor class now dominating new prescriptions. Novartis continues to post revenue growth from Cosentyx. Other major manufacturers in the dermatology space include Johnson & Johnson, Pfizer, Eli Lilly, Galderma, Bristol-Myers Squibb, and LEO Pharma.
Psoriasis dominates the global dermatological drugs market due to its substantial prevalence worldwide and the high proportion of patients requiring advanced biologic therapies. Psoriasis represents the largest indication in the global dermatological drugs market. Approximately 125 million people worldwide suffer from psoriasis, representing 2% to 3% of the global population. The global psoriasis treatment market exceeded $29 billion in 2025, with biologics accounting for approximately 44% of the total. The IL-23 inhibitor class now dominates new prescriptions. Plaque psoriasis affects 85% to 90% of all psoriasis patients. The chronic, systemic nature of psoriasis necessitates long-term treatment, driving sustained prescription volumes. Approximately 20% to 30% of psoriasis patients develop psoriatic arthritis, expanding the therapeutic addressable population. The availability of biologic therapies, including IL-17 and IL-23 inhibitors, has expanded treatment options for moderate-to-severe cases. Increasing awareness and earlier diagnosis continue to expand the addressable patient population globally.
Calcineurin inhibitors are experiencing rapid global growth driven by their steroid-sparing properties and expanding approval for pediatric atopic dermatitis management. Calcineurin inhibitors have emerged as the fastest-growing drug class in the global dermatological drugs market. These agents offer effective steroid-sparing alternatives for managing atopic dermatitis. Atopic dermatitis affects over 230 million people worldwide, with prevalence reaching up to 20% of children and nearly 10% of adults globally. The class addresses steroid phobia, a significant barrier to treatment adherence reported across multiple global markets. Calcineurin inhibitors are particularly valuable for treating sensitive areas including the face and intertriginous regions. The rising global prevalence of atopic dermatitis drives sustained demand across all geographic regions. These therapies offer favorable safety profiles for long-term use in pediatric populations. The expanding therapeutic indications for calcineurin inhibitors across multiple dermatological conditions continue to drive market growth.
Topical administration maintains global market leadership due to patient preference for non-invasive therapy and the substantial burden of mild-to-moderate skin conditions. Topical administration represents the largest route of administration in the global dermatological drugs market. Topical therapies offer targeted delivery to affected areas, minimizing systemic exposure and side effects. Patient preference for non-invasive, self-administered treatments drives topical product adoption across all global regions. The availability of diverse topical formulations provides therapeutic options for various skin types and conditions. The FDA approved roflumilast 0.3% foam for plaque psoriasis of the scalp and body in patients 12 years and older. The approval of Anzupgo as the first topical JAK inhibitor for chronic hand eczema demonstrates continued innovation in topical therapies. Topical therapies are particularly valuable in regions with limited healthcare infrastructure. The development of novel topical formulations with enhanced penetration continues to expand the therapeutic arsenal.
Prescription dermatological drugs are experiencing accelerated global growth driven by innovative biologics, JAK inhibitors, and targeted therapies requiring medical supervision. Prescription-based dermatological drugs dominate the global market due to the complexity of chronic skin conditions. Innovative biologics and JAK inhibitors require prescription status due to their potent mechanisms and potential side effect profiles. The complexity of chronic skin conditions necessitates physician-guided treatment selection and ongoing monitoring across global healthcare systems. Prescription drugs offer superior efficacy compared to over-the-counter alternatives for moderate-to-severe dermatological conditions. The expanding indications for prescription biologics drive sustained prescription volume growth across all global regions. Reimbursement policies across developed and emerging markets favor prescription-based treatments. Dermatologists increasingly rely on prescription therapies as first-line interventions for chronic inflammatory skin diseases. Regulatory approvals of novel prescription therapies across all major regions continue to expand the therapeutic landscape.
Online pharmacies are experiencing explosive global growth driven by digital health adoption, convenience, and expanding e-commerce infrastructure across all regions. Online pharmacies represent the fastest-growing distribution channel in the global dermatological drugs market. The COVID-19 pandemic accelerated digital health adoption globally, normalizing online pharmacy usage. Online platforms offer competitive pricing and home delivery, addressing accessibility challenges in remote areas. The integration of telemedicine with online pharmacy services enables seamless prescription fulfillment. Rising smartphone penetration and internet connectivity across emerging markets support online pharmacy growth. Consumer preference for discreet purchasing of dermatological products drives online channel adoption. Regulatory frameworks across global regions are evolving to accommodate and regulate online pharmaceutical distribution. Online platforms are expected to significantly reshape global distribution dynamics in the coming years.
According to the research report "Global Dermatological Drugs Market Outlook, 2031," published by Bonafide Research, the Global Dermatological Drugs market was valued at more than USD 32.76Billion in 2025, and expected to reach a market size of more than USD 50.98 Billion by 2031 with the CAGR of 7.84% from 2026-2031. The year 2025 marked a remarkable period of innovation in dermatology, with regulatory authorities worldwide granting approvals for a wide range of therapies spanning chronic inflammatory skin diseases, rare genetic disorders, and oncology. These approvals reflect significant advancements in targeted treatments, biologics, gene therapy, and device-based interventions. The U.S. Food and Drug Administration approved several groundbreaking dermatological therapies in 2025. In April, the FDA approved prademagene zamikeracel (Zevaskyn; Abeona Therapeutics) as the first autologous, cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), marking a monumental advance in regenerative dermatology. The phase 3 VIITAL study demonstrated that 81% of wounds treated with Zevaskyn showed 50% or more healing at six months compared with 16% of matched control wounds treated with standard of care. In July, LEO Pharma secured FDA approval for Anzupgo (delgocitinib) cream as the first and only treatment for chronic hand eczema in adults. This topical pan-JAK inhibitor offers a steroid-free option for patients who have not responded adequately to traditional topical treatments. Additional notable approvals included dupilumab (Dupixent; Regeneron and Sanofi) for chronic spontaneous urticaria in patients 12 years and older—the first new targeted therapy for CSU in more than a decade and roflumilast 0.3% foam (Zoryve; Arcutis Biotherapeutics) for plaque psoriasis of the scalp and body in patients 12 years and older, marking the first branded topical foam for psoriasis. AbbVie continues to demonstrate exceptional performance in the immunology space, with its sixth-place revenue ranking largely credited to the success of Skyrizi and Rinvoq. The psoriasis treatment market exceeded $29 billion in 2025, with biologics accounting for approximately 44% of the total and the IL-23 inhibitor class now dominating new prescriptions. Novartis continues to post revenue growth from Cosentyx. Other major manufacturers in the dermatology space include Johnson & Johnson, Pfizer, Eli Lilly, Galderma, Bristol-Myers Squibb, and LEO Pharma.
Psoriasis dominates the global dermatological drugs market due to its substantial prevalence worldwide and the high proportion of patients requiring advanced biologic therapies. Psoriasis represents the largest indication in the global dermatological drugs market. Approximately 125 million people worldwide suffer from psoriasis, representing 2% to 3% of the global population. The global psoriasis treatment market exceeded $29 billion in 2025, with biologics accounting for approximately 44% of the total. The IL-23 inhibitor class now dominates new prescriptions. Plaque psoriasis affects 85% to 90% of all psoriasis patients. The chronic, systemic nature of psoriasis necessitates long-term treatment, driving sustained prescription volumes. Approximately 20% to 30% of psoriasis patients develop psoriatic arthritis, expanding the therapeutic addressable population. The availability of biologic therapies, including IL-17 and IL-23 inhibitors, has expanded treatment options for moderate-to-severe cases. Increasing awareness and earlier diagnosis continue to expand the addressable patient population globally.
Calcineurin inhibitors are experiencing rapid global growth driven by their steroid-sparing properties and expanding approval for pediatric atopic dermatitis management. Calcineurin inhibitors have emerged as the fastest-growing drug class in the global dermatological drugs market. These agents offer effective steroid-sparing alternatives for managing atopic dermatitis. Atopic dermatitis affects over 230 million people worldwide, with prevalence reaching up to 20% of children and nearly 10% of adults globally. The class addresses steroid phobia, a significant barrier to treatment adherence reported across multiple global markets. Calcineurin inhibitors are particularly valuable for treating sensitive areas including the face and intertriginous regions. The rising global prevalence of atopic dermatitis drives sustained demand across all geographic regions. These therapies offer favorable safety profiles for long-term use in pediatric populations. The expanding therapeutic indications for calcineurin inhibitors across multiple dermatological conditions continue to drive market growth.
Topical administration maintains global market leadership due to patient preference for non-invasive therapy and the substantial burden of mild-to-moderate skin conditions. Topical administration represents the largest route of administration in the global dermatological drugs market. Topical therapies offer targeted delivery to affected areas, minimizing systemic exposure and side effects. Patient preference for non-invasive, self-administered treatments drives topical product adoption across all global regions. The availability of diverse topical formulations provides therapeutic options for various skin types and conditions. The FDA approved roflumilast 0.3% foam for plaque psoriasis of the scalp and body in patients 12 years and older. The approval of Anzupgo as the first topical JAK inhibitor for chronic hand eczema demonstrates continued innovation in topical therapies. Topical therapies are particularly valuable in regions with limited healthcare infrastructure. The development of novel topical formulations with enhanced penetration continues to expand the therapeutic arsenal.
Prescription dermatological drugs are experiencing accelerated global growth driven by innovative biologics, JAK inhibitors, and targeted therapies requiring medical supervision. Prescription-based dermatological drugs dominate the global market due to the complexity of chronic skin conditions. Innovative biologics and JAK inhibitors require prescription status due to their potent mechanisms and potential side effect profiles. The complexity of chronic skin conditions necessitates physician-guided treatment selection and ongoing monitoring across global healthcare systems. Prescription drugs offer superior efficacy compared to over-the-counter alternatives for moderate-to-severe dermatological conditions. The expanding indications for prescription biologics drive sustained prescription volume growth across all global regions. Reimbursement policies across developed and emerging markets favor prescription-based treatments. Dermatologists increasingly rely on prescription therapies as first-line interventions for chronic inflammatory skin diseases. Regulatory approvals of novel prescription therapies across all major regions continue to expand the therapeutic landscape.
Online pharmacies are experiencing explosive global growth driven by digital health adoption, convenience, and expanding e-commerce infrastructure across all regions. Online pharmacies represent the fastest-growing distribution channel in the global dermatological drugs market. The COVID-19 pandemic accelerated digital health adoption globally, normalizing online pharmacy usage. Online platforms offer competitive pricing and home delivery, addressing accessibility challenges in remote areas. The integration of telemedicine with online pharmacy services enables seamless prescription fulfillment. Rising smartphone penetration and internet connectivity across emerging markets support online pharmacy growth. Consumer preference for discreet purchasing of dermatological products drives online channel adoption. Regulatory frameworks across global regions are evolving to accommodate and regulate online pharmaceutical distribution. Online platforms are expected to significantly reshape global distribution dynamics in the coming years.
Related Press Releases
Clinical workflow market expands on rising healthcare automation
Lifescience & Healthcare
Ayurvedic products market expands on rising natural wellness and preventive care demand.
Lifescience & Healthcare
Quick Contacts
Trusted Partners
Latest Press Release
We are friendly and approachable, give us a call.